share_log

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

涅槃生命科學公司宣佈任命謝爾頓·因文塔什為董事會成員
newsfile ·  2022/11/09 22:00

Vancouver, British Columbia--(Newsfile Corp. - November 9, 2022) - Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.

加拿大不列顛哥倫比亞省温哥華-(Newsfile Corp.-2022年11月9日)-總部位於加拿大的旨在開發非成癮性慢性疼痛和復發預防產品的生命科學公司Nirvana Life Science Inc.(CSE:NIRV)(Nirvana或“公司”)高興地宣佈任命Sheldon Inwentash先生為公司董事會成員。

Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies.

Inwentash先生是ThreeD Capital Inc.的創始人、董事長兼首席執行官。作為一名經驗豐富的企業家,謝爾頓擁有30多年的成功投資經驗,在為他的投資者實現可觀的ROI和為他投資的公司實現盈利方面有着廣泛的記錄。他創立了ThreeD Capital,在幾個領域提供獨特的投資機會,特別是小盤股、資源和顛覆性技術的早期階段。

Well-regarded in the investment industry, Sheldon has earned a reputation for creating significant shareholder value through early investments, having financed hundreds of public and private start-up companies, many of which went on to have successful exits.

謝爾頓在投資界享有盛譽,他通過早期投資創造了巨大的股東價值,為數百家上市和私人初創公司提供了資金,其中許多公司後來成功退出。

Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.

謝爾頓畢業於多倫多大學,獲得通信學士學位,後來被授予該大學榮譽法學博士學位,以表彰他作為企業家和慈善家的領導能力以及對青年的奉獻精神。

Mr. Inwentash commented, "I am very excited for the opportunity to join the board of Nirvana. As an early investor of the Company, I have seen the commitment and dedication of the Nirvana team to developing psychedelic formulations to treat addiction and manage pain. Nirvana's innovative approach to fighting the opioid crisis and other forms of addiction is revolutionary and positions the Company as a leader in the psychedelic healthcare industry". 

Inwentash先生評論説:“我對有機會加入Nirvana董事會感到非常興奮。作為公司的早期投資者,我看到了Nirvana團隊致力於開發治療成癮和控制疼痛的迷幻配方的承諾和奉獻。Nirvana對抗阿片類藥物危機和其他形式的成癮的創新方法是革命性的,使公司成為迷幻保健行業的領先者。”

Mr. Bruce Clark, Chief Executive Officer of Nirvana commented, "We are pleased that Mr. Inwentash has chosen to join our Board, he brings a clear understanding of the value that alternative therapies can play in the treatment of addiction and management of chronic pain. His experience with disruptive technologies will be impactful as we move to the next phase of our development".

Nirvana首席執行官布魯斯·克拉克先生評論説:“我們很高興Inwentash先生選擇加入我們的董事會,他清楚地認識到替代療法在治療成癮和控制慢性疼痛方面的價值。他在顛覆性技術方面的經驗將在我們進入發展的下一個階段時產生影響。”

For further information:
Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100

有關更多信息,請訪問:
布魯斯·克拉克--首席執行官
郵箱:info@nirvanalyifescience.com
電話:604-401-8100

About Nirvana Life Sciences Inc.

涅槃生命科學公司簡介

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana's team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.

Nirvana生命科學公司成立的目的很簡單,就是研究和開發非成癮性疼痛管理和復發預防產品,為患有慢性疼痛和/或與毒癮作鬥爭的患者提供更健康的結果。涅槃認為,在新配方中使用天然來源的迷幻劑有望提供有效控制疼痛和成癮的非成癮解決方案。涅槃的團隊由來自全球各地的頂尖研究人員組成,他們將開發有可能使數百萬人擺脱毒癮並每年為社會節省數十億美元的療法。

Forward Looking Statements

前瞻性陳述

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

本新聞稿包含加拿大證券法定義的某些前瞻性陳述和前瞻性信息(本文統稱為“前瞻性陳述”),包括但不限於與公司未來投資有關的陳述。除歷史事實以外的所有陳述均為前瞻性陳述。不應過分依賴前瞻性陳述,因為這些陳述本身是不確定的,基於估計和假設,並受到已知和未知風險和不確定性(一般和具體的)的影響,這些風險和不確定性導致前瞻性陳述中預期的未來事件或情況可能不會發生。儘管公司相信本新聞稿中包含的前瞻性陳述中反映的預期以及做出這些前瞻性陳述所依據的假設是合理的,但不能保證這些預期將被證明是正確的。告誡讀者不要過度依賴本文件中包含的前瞻性陳述,因為不能保證前瞻性陳述所依據的計劃、意圖或預期將會發生。就其性質而言,前瞻性陳述涉及許多假設、已知和未知的風險和不確定性,這些風險和不確定性導致預測、預測、預測和其他前瞻性陳述不會發生的可能性。, 這可能會導致公司未來的實際業績和結果與此類前瞻性陳述明示或暗示的對未來業績或結果的任何估計或預測大不相同。本新聞稿中包含的前瞻性陳述是截至本新聞稿發佈之日作出的,公司不承擔公開更新或修改任何包含的前瞻性陳述的義務,除非適用法律要求。本文中包含的前瞻性陳述明確地受到這一警告性聲明的限制。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論